Top Stories
The wins came for the combination of Tagrisso (osimertinib) and Orpathys (savolitinib) in the SAFFRON study, as well as Enhertu (trastuzumab deruxtecan) in DESTINY-Lung04.
Subcutaneous version of the FcRn inhibitor delivered notable improvements on disease activity, including in the immune-mediated necrotising myopathy subtype.
Aizen's DaX model will be used to design candidates for immunology and neurology programmes.
Felzartamab was approved in combination with lenalidomide and dexamethasone to treat adults with multiple myeloma who have received at least one prior line of therapy.
The maker of cardiomyopathy drug Myqorzo is challenging BMS's patent while former Celgene shareholders get a positive court ruling over their long-standing claims about a missed payout.
Conference News
$7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR ®$17 million in cash and cash equivalents as of June 30, 2026Expanded LYMPHIR commercial and medical a...
-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed® fertility portfolio and advancement of the FemBloc® clinical and regulatory program toward U.S. approval --ATLA...
STATEN ISLAND, N.Y., Aug. 14, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics f...
The combined company, Fibrx Therapeutics, will start a Phase II trial of RXC008 in fibrostenotic Crohn’s disease.
- Completed quarter with $26.9 million in cash and restricted cash- Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP® companion diagnostic i...
